Chemotherapy drug response in ovarian cancer cells strictly depends on a cathepsin D-Bax activation loop

Roberta Castino1, Claudia Peracchio, Alessandra Salini

  • 1Department of Medical Sciences, "A. Avogadro" University, Novara, Italy.

Insights

Chemosensitive ovarian cancer cells activate a Cathepsin D (CD)-Bax pathway, leading to lysosome and mitochondrial permeabilization. Chemoresistant cells bypass this, highlighting lysosomal dysfunction in drug resistance.

Area of Science:

  • Cell Biology
  • Cancer Research
  • Biochemistry

Background:

  • Ovarian cancer cell lines A2780 (wild-type p53) and NIHOVCAR3 (mutated p53) exhibit differential sensitivity to chemotherapy.
  • The intrinsic cell death pathway's activation mechanism in response to chemotherapy remains incompletely understood.

Purpose of the Study:

  • To investigate the role of the lysosome-mitochondrion signaling pathway in chemoresistance.
  • To elucidate the molecular mechanisms underlying differential drug sensitivity in ovarian cancer cells.

Main Methods:

  • Pharmacological inhibition and genetic manipulation of key regulators in the lysosome-mitochondrion pathway.
  • Biochemical assays and confocal fluorescence microscopy to study protein expression and localization.
  • Analysis of cell viability and apoptosis markers following chemotherapy treatment.

Main Results:

  • Chemosensitive A2780 cells showed high Bax and low Bcl-2 expression, while resistant NIHOVCAR3 cells had high Bcl-2 and low Bax.
  • Cathepsin D (CD) mediated mitochondrial death pathway activation in A2780 cells.
  • Lysosome leakage and cytosolic CD relocation occurred in chemosensitive cells, but not resistant cells.
  • Bax was essential for lysosomal and mitochondrial permeabilization, and CD activity was mandatory for Bax oligomerization in A2780 cells.

Conclusions:

  • A Cathepsin D-Bax signaling loop drives lysosomal and mitochondrial permeabilization, initiating apoptosis in chemosensitive ovarian cancer cells.
  • Dysfunctional lysosomal permeabilization contributes to chemoresistance in ovarian cancer.
  • Targeting the CD-Bax pathway could offer novel therapeutic strategies for overcoming ovarian cancer chemoresistance.

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...